Ameresco, Inc. (NYSE:AMRC): Oppenheimer notes that Amerseco’s awarded backlogs and new proposals have increased by double digits. The firm expects the company’s revenue to increase by mid-teens levels for the next several years and it maintains a $17 target and Outperform rating.

Augme Technologies Inc (OTC:AUGT): Brean Murray raised its price target on Augme Technologies (AUGT) following its favorable ruling in its lead infringement case which could now go to trial. The case could lead to a settlement with AOL (NYSE:AOL) in excess of $300M while the company has identified an additional 640 potential infringers. Shares are Buy rated.

Intel Corporation (NASDAQ:INTC): Baird reduced its 2H2012 estimates for Intel to reflect weakness in Europe which is negatively impacting the PC supply chain. The firm also cited weakness in China and a lower than expected adoption rate for Ultrabooks. Baird maintains its Outperform rating and $33 price target and said the valuation remains attractive.

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN): Rodman & Renshaw sees significant risk of Amylin’s final buyout price being below current share levels. The firm believes investors putting new money to work in Amylin are exposed to more downside risk than upside potential and keeps an Underperform rating on the stock with a $22 price target.

Joy Global, Inc. (NASDAQ:JOY): After Joy Global reported higher than expected Q2 adjusted EPS, BMO Capital believes that the outlook for the underground U.S. coal market is stabilizing, while key international mining markets remain strong. The firm lowered its target on the stock to $90 from $100 but maintains an Outperform rating.